World
CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
AIDS Vaccine Advocacy Coalition calls for Viread trials to continue
Although worldwide clinical trials of the anti-HIV drug Viread are drawing criticism from AIDS activists, the AIDS Vaccine Advocacy Coalition on Thursday issued a report that calls for the studies to continue, as the drug is still a possible way to prevent HIV infections. The report, titled "Will a Pill a Day Prevent HIV? Anticipating the Results of the Tenofovir PREP Trials," examines the issues and ethical concerns raised by some activists, particularly whether sex workers and injection-drug users in developing countries participating in the trials are being adequately counseled on safer sex, and whether those who become infected during the study should be given free lifetime supplies of antiretroviral drugs. AVAC says these issues can be adequately addressed by trial organizers and funders, and that the studies should continue with more concerted coordination and advance planning to accelerate data evaluation.
"The concerns raised about the trials are serious, and there is a need for thorough and unbiased investigation," said Mitchell Warren, AVAC executive director, in a press statement. "But all of the concerns raised are solvable. AVAC calls on researchers, communities, and advocates to work together to ensure that ethical concerns are addressed, solutions are found, and the trials go forward."
The studies, under way among sexually active gay men in the United States, female sex workers in Africa, and injection-drug users in Thailand, aim to determine whether daily doses of Viread are effective in preventing HIV infections that are transmitted through sexual contact or needle sharing. The AVAC report says that the World Health Organization, the Joint United Nations Programme on HIV/AIDS, the trial sponsors, and other organizations should work together to ensure that research and trials are coordinated and progress in an accelerated fashion--and that additional research is carried out in an expedited fashion--to ensure that it is known as soon as possible if Viread is a safe and effective HIV prevention intervention.
"We need as many HIV prevention tools as possible, so research on vaccines, microbicides, and other potential interventions must also be accelerated whether or not Viread proves appropriate for preexposure prophylaxis," Warren said.
The AVAC report is available online at www.avac.org and in print by sending a request via e-mail to avac@avac.org.
From our Sponsors
Most Popular
31 Period Films of Lesbians and Bi Women in Love That Will Take You Back
December 09 2024 1:00 PM
18 of the most batsh*t things N.C. Republican governor candidate Mark Robinson has said
October 30 2024 11:06 AM
True
After 20 years, and after tonight, Obama will no longer be the Democrats' top star
August 20 2024 12:28 PM
Trump ally Laura Loomer goes after Lindsey Graham: ‘We all know you’re gay’
September 13 2024 2:28 PM
Melania Trump cashed six-figure check to speak to gay Republicans at Mar-a-Lago
August 16 2024 5:57 PM
These 15 major companies caved to the far right and stopped DEI programs
January 24 2025 1:11 PM
True
Latest Stories
​'Heightened Scrutiny' is a somber reminder of why we fight for trans rights
February 06 2025 6:31 PM
NCAA caves and says it will obey Trump order banning trans athletes
February 06 2025 4:54 PM
Vision for long-delayed memorial to Pulse victims finally comes into view
February 06 2025 4:34 PM
Publishers and library sue Idaho over book ban that defines 'homosexuality' as 'harmful to minors'
February 06 2025 12:35 PM
Anti-trans Republican Nancy Mace doubles down on dehumanizing transphobic slur during hearing
February 06 2025 10:27 AM